- Home
- INCR vs VTGN Comparison
INCR vs VTGN Comparison
Compare INCR & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- VTGN
- Stock Information
- Founded
- INCR 1994
- VTGN 1998
- Country
- INCR Israel
- VTGN United States
- Employees
- INCR N/A
- VTGN N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- VTGN Biotechnology: Pharmaceutical Preparations
- Sector
- INCR Health Care
- VTGN Health Care
- Exchange
- INCR Nasdaq
- VTGN Nasdaq
- Market Cap
- INCR 76.7M
- VTGN 81.3M
- IPO Year
- INCR N/A
- VTGN N/A
- Fundamental
- Price
- INCR $1.70
- VTGN $2.92
- Analyst Decision
- INCR
- VTGN
- Analyst Count
- INCR 0
- VTGN 0
- Target Price
- INCR N/A
- VTGN N/A
- AVG Volume (30 Days)
- INCR 43.9K
- VTGN 401.9K
- Earning Date
- INCR 02-15-2025
- VTGN 02-11-2025
- Dividend Yield
- INCR N/A
- VTGN N/A
- EPS Growth
- INCR N/A
- VTGN N/A
- EPS
- INCR N/A
- VTGN N/A
- Revenue
- INCR $72,420,918.00
- VTGN $876,000.00
- Revenue This Year
- INCR N/A
- VTGN N/A
- Revenue Next Year
- INCR $39.30
- VTGN N/A
- P/E Ratio
- INCR N/A
- VTGN N/A
- Revenue Growth
- INCR N/A
- VTGN 8.08
- 52 Week Low
- INCR $1.17
- VTGN $2.22
- 52 Week High
- INCR $3.72
- VTGN $5.74
- Technical
- Relative Strength Index (RSI)
- INCR 57.80
- VTGN 53.24
- Support Level
- INCR $1.63
- VTGN $2.40
- Resistance Level
- INCR $1.75
- VTGN $3.40
- Average True Range (ATR)
- INCR 0.07
- VTGN 0.21
- MACD
- INCR 0.01
- VTGN -0.00
- Stochastic Oscillator
- INCR 64.57
- VTGN 47.83
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.